Find investors
← Back to all investors
KI
ResearchedAngel Investors

Kiril Ip

COO

Angel InvestorsSeed Round
Pitch Kiril

Get their honest, personalized take on your startup.

Sign in to pitch Kiril

At a glance

Full Name
Kiril Ip
Title
Co-founder & Chief Operating Officer (COO)
Firm
Forebright Capital (Forebright Capital Management Limited)
Firm Type
Institutional private equity fund manager — middle-market growth equity (note: the source stub labeled this "Angel Investors," but every available source describes Forebright as a growth-stage PE firm, not an angel/seed investor)
Investment Stage
Growth / expansion stage (the firm and its team also participate in later private rounds and pre-IPO deals)
Check Size
Reported at roughly US$10M–US$50M per deal
Target Company Profile
Established, revenue-generating Chinese middle-market companies with strong management teams and long-term growth potential
Sector Focus
Healthcare / tech-driven healthcare, technology, advanced manufacturing, fintech, and consumer
Geographic Focus
Greater China (Mainland China and Hong Kong)
Location
Hong Kong (firm HQ); Kiril is also associated with the firm's Shenzhen, Guangdong operations

Background

Kiril Ip is a co-founder and the Chief Operating Officer of Forebright Capital, a Hong Kong–headquartered institutional-quality private equity firm focused on Chinese middle-market growth investments. Forebright was spun out in May 2014 from China Everbright Limited, a state-owned enterprise listed on the Hong Kong Stock Exchange, where the founding team had already invested together for more than a decade. Prior to co-founding Forebright, Kiril was a Managing Director at China Everbright Limited.

At Forebright, Kiril's remit centers on the operational and legal backbone of the fund. He oversees the legal aspects of fund operations, including deal structuring, negotiation of investments, transaction documentation, and managing the performance of external counsel — a natural fit given his legal training.

Kiril's background is unusually cross-disciplinary. He has been qualified as a solicitor in Hong Kong for over 17 years and combines that legal expertise with a Master's degree in Transport Management and a Bachelor's degree in Mechanical Engineering. This mix of engineering, operations, and law underpins his role running the firm's operational and compliance functions rather than sourcing deals as a front-line investor.

Forebright manages capital on behalf of global institutional investors — including sovereign wealth funds, insurance companies, pension funds, university and corporate endowments, and funds of funds — positioning the firm as a professionally managed, LP-backed vehicle rather than a personal angel investor.

Investment Thesis & Focus

  • Invests as a growth private equity firm, not an angel/seed investor — targeting established, cash-generative Chinese middle-market companies rather than pre-revenue startups.
  • Sector emphasis on healthcare and tech-driven healthcare, technology, advanced manufacturing, fintech, and consumer businesses.
  • Check sizes reported in the ~US$10M–US$50M range, consistent with growth-equity and expansion rounds.
  • Value-add approach: the firm states it is "committed to partnering with business leaders, providing value-added services, and contributing to the long-term growth of outstanding enterprises in China."
  • Geographic focus squarely on Greater China (Mainland China + Hong Kong).
  • Kiril's specific contribution is on the operational/legal side — deal structuring, negotiation, documentation, and fund governance — rather than thematic deal-sourcing.

Notable Investments

  • BGI Genomics (SZSE: 300676) — Chinese genomics and gene-sequencing company; publicly listed.
  • Kindstar Globalgene (HKEX: 9960) — specialty clinical (esoteric) diagnostics testing provider in China; IPO'd on the Hong Kong Stock Exchange.
  • Sirnaomics (HKEX: 2257) — RNAi therapeutics biotech; publicly listed in Hong Kong.
  • WestVac (WestVac Biopharma) — Chengdu-based vaccine and biopharmaceutical developer.
  • EPG — most recent reported investment, a Series B round dated January 27, 2026.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.